Shares Of Sarepta Declined On New Phase 2 Data, Is The Drop Justified?
January 16, 2015 at 13:42 PM EST
Shares of Sarepta have fallen sharply after releasing New study data for Eteplirsen targeting Duchenne Muscular Dystrophy, but the drop is not warranted.
